A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

Launched by ASTRAZENECA · Dec 21, 2022

Keywords

ClinConnect Summary

This clinical trial, called EXCEED, is studying the risk of pancreatic cancer in patients with type 2 diabetes who start a medication called exenatide compared to those who start other diabetes medications. The researchers want to understand if there is a difference in the risk of developing pancreatic cancer between these two groups. They will collect health data from patients in seven European countries, looking at those who began their diabetes treatment between 2006 and 2023. To participate, individuals must be at least 18 years old, have been diagnosed with type 2 diabetes, and have health records available for at least a year before starting treatment.

If eligible, participants can expect their health information related to diabetes treatments and any diagnoses to be analyzed over time. It's important to note that certain health conditions, like type 1 diabetes or a history of cancer (with some exceptions), may exclude someone from participating. The goal of this study is to ensure that patients and their doctors have a clear understanding of the potential risks associated with exenatide compared to other diabetes medications.

Gender

ALL

Eligibility criteria

• For inclusion in either exposure group, all of the following inclusion criteria must be fulfilled:
• • 1. Aged 18 years or older at the index date
• • 2. Individual level data on prescriptions, diagnoses and medical history is available for a minimum of 12 months prior to the index date
• • 3. A diagnosis of T2DM on index date or prior to index date
• For inclusion in the overall exenatide exposure group, the following criterion must be fulfilled:
• • 1. One incident prescription (or incident dispensed prescription) for exenatide (BYETTA or BYDUREON/ BYDUREON BCise) between the start and 12 months before the end of the study period. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period.
• For inclusion in the BYDUREON/ BYDUREON BCise exposure group, for the analyses of the secondary objective, the criterion a) is substituted with criterion b):
• • 2. One incident prescription (or incident dispensed prescription) for BYDUREON/ BYDUREON BCise between the start and 12 months before the end of the study period. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period.
• For inclusion in the comparator group, the following criterion must be fulfilled:
• • 3. One incident prescription (or incident dispensed prescription) of a GLD between the start and 12 months before the end of the study period. The GLD must not be a DPP-4i, a GLP-1 RA, or a combination with either a DPP-4i or a GLP-1 RA. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period.
• Patients are not eligible for any of the study population groups if they fulfil any of the following exclusion criteria:
• • 1. A diagnosis of type 1 diabetes mellitus (T1DM) on index date or a diagnosis of T1DM during the baseline period that is not succeeded by a T2DM diagnosis during the remaining part of the baseline period.
• • 2. A diagnosis of gestational diabetes during the baseline period or on index date.
• • 3. A diagnosis of polycystic ovarian syndrome during the baseline period or on index date in combination with exposure to metformin (Anatomical Therapeutic Chemical Classification System (ATC) code of the World Health Organization (WHO): A10BA02) as the only GLD on index date or during the baseline period.
• • 4. History of any cancer on or prior to index date. The only exception is that nonmelanoma skin cancer does not lead to exclusion.
• • 5. History of any acute pancreatitis, other diseases of the pancreas, or disorders of the pancreas on or prior to index date.
• • 6. One or more prescriptions (or dispensed prescriptions) of a GLP-1 RA (incretin mimetics) other than exenatide on or prior to index date.
• • 7. One or more prescriptions (or dispensed prescriptions) of DPP-4i (incretin mimetics) on or prior to the index date.